Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
about
Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeuticsNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewSilencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphomaA new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cellsRaf kinase inhibitory protein regulates aurora B kinase and the spindle checkpointTemsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival.Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase-1/2 activity via 4-hydroxynonenal.Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasRKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapySorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytesThe novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaGlycogen synthase kinase-3β is a prosurvival signal for the maintenance of human mast cell homeostasisMEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyAcidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk.Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.Can we develop biomarkers that predict response of cancer patients to immunotherapy?B lymphocytes as therapeutic targets in systemic lupus erythematosus.Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.Reduced RKIP enhances nasopharyngeal carcinoma radioresistance by increasing ERK and AKT activity.A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis.Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor.In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.Human interleukin 23 receptor induces cell apoptosis in mammalian cells by intrinsic mitochondrial pathway associated with the down-regulation of RAS/mitogen-activated protein kinase and signal transducers and activators of transcription factor 3 siMolecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.Understanding and circumventing resistance to anticancer monoclonal antibodies.RKIP: much more than Raf kinase inhibitory protein.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
P2860
Q26782525-1255B617-9C4E-478D-A9A9-FCFF6D75C531Q27304386-97D1CEB6-804D-478B-80C6-39F83AF64543Q28486745-518F0E1B-F5FB-494C-9514-27DB2816B100Q28541630-DED4F814-4FB5-4DAC-A500-648CBE86B815Q28567156-D9A4C07C-DA32-4B2B-9F11-3E72AD4C0202Q33394663-800EBBA3-6AF8-4F6F-A409-68FC56514ABFQ33401136-8E8D93DA-E954-471C-B6B0-15D15A1E2F9CQ33731418-6A4FDCD4-FE39-499C-A2B3-1F8938E10787Q33937454-11A7F57C-6AD1-4B3C-9954-0C856E82273DQ34206982-38CF7E9C-C637-40C4-B7D5-5FAE2FDCCA4FQ34326588-570691BE-1B9D-486A-9884-DB3C7E90CF35Q34369841-2B4C4C8D-0751-45EF-A8C0-1222B0853295Q34634649-C1D47A15-2FEC-4506-9E58-FD1FD63075CCQ34689078-0A64BBDC-1CD5-4C7B-92E8-55B45E96F7C9Q34700655-ED0C7D3A-F6F7-4118-80FA-DE4467B03C7BQ34707611-F92CBF8A-C26B-4CFB-A396-6CB3792B022FQ35140947-5BB39012-6ECC-4C56-922D-3EA310258CD5Q35566591-DE6B734C-2928-42ED-AAE1-4E8B72A7D249Q35804449-26FE6A03-606D-445F-8E1F-028EE4A79DB1Q35835983-9231494C-06E5-4262-ABA2-3FE53789FE9EQ35849663-2BFC43FD-4544-42A6-BC30-29F64E9BF186Q36201760-279709E7-E73D-4C4B-B744-EFA48C36C191Q36254232-772B052B-A413-40E1-BCCA-4341BFC22816Q36318014-6CAD671E-0371-4CFA-AAE3-76A397BC0EB6Q36653646-3ECA7262-695B-41BE-B117-22E8598E48D6Q36832106-DF6CB666-965D-4D38-BC84-33E3EEA9F33AQ36998275-E448EFC7-FA6B-4BDF-BD37-6FE832FC82DAQ37028557-F422506D-50CB-475E-8F4C-924DCF744D0BQ37068080-A2A0BA9A-2932-43C8-99CB-CFC258C551E7Q37124492-7240AB13-2E73-4044-8556-F2CB3510228EQ37162216-1B9A0AF8-FD15-4C87-AF7C-C6F16F26C35BQ37262987-29AEB2BB-D2B1-4071-9DE1-5B54EE04D04EQ37421049-98C93420-E8CA-4BE6-A84B-8B1F8259763BQ37448352-D6CF4E5E-C298-43AE-81C7-C15BDEADDA53Q37586857-8593E56C-6991-451B-9338-BA6222BFE05AQ37613872-B32D6297-E275-4215-AC62-138F532EB304Q37672125-1A6FC53F-0528-4923-BD09-47AF727AE21CQ38077517-3E2320D2-0AA8-4A49-B3E4-FAAA0820661CQ38126946-6C0AE03F-EA3A-48E8-9C49-9331E9C2991CQ38132359-2A87133C-22C3-4638-8A67-7C90E1D69D4D
P2860
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Inhibition of the Raf-MEK1/2-E ...... lymphoma B cells by Rituximab.
@en
type
label
Inhibition of the Raf-MEK1/2-E ...... lymphoma B cells by Rituximab.
@en
prefLabel
Inhibition of the Raf-MEK1/2-E ...... lymphoma B cells by Rituximab.
@en
P2093
P1433
P1476
Inhibition of the Raf-MEK1/2-E ...... lymphoma B cells by Rituximab
@en
P2093
Ali R Jazirehi
Benjamin Bonavida
Devasis Chatterjee
Lee Goodglick
P304
P356
10.1158/0008-5472.CAN-03-3500
P407
P577
2004-10-01T00:00:00Z